UR-144

UR-144
Clinical data
Trade names	different brandnames, typical example: "TMCP-018", "KM-X1", "UR-144", "MN-001", "YX-17"
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); CA: Schedule II; DE: Anlage II (Authorized trade only, not prescriptible); NZ: Temporary Class; UK: Class B; US: Schedule I;
Identifiers
	IUPAC name (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone;
CAS Number	1199943-44-6 ;
PubChem CID	44626619;
ChemSpider	24634882 ;
UNII	1TYA7HVP1B;
KEGG	C22781 ;
ChEMBL	ChEMBL571773 ;
CompTox Dashboard (EPA)	DTXSID60152635 ;
Chemical and physical data
Formula	C21H29NO
Molar mass	311.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCN1C=C(C2=CC=CC=C21)C(=O)C3C(C3(C)C)(C)C;
	InChI InChI=1S/C21H29NO/c1-6-7-10-13-22-14-16(15-11-8-9-12-17(15)22)18(23)19-20(2,3)21(19,4)5/h8-9,11-12,14,19H,6-7,10,13H2,1-5H3 ; Key:NBMMIBNZVQFQEO-UHFFFAOYSA-N ;
	(what is this?)

UR-144 (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB₂, but with much lower affinity for the psychoactive CB₁ receptor.